These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 31678168)

  • 1. PD-L1
    Zhang L; Zhang X; Liu Y; Zhang T; Wang Z; Gu M; Li Y; Wang DD; Li W; Lin PP
    Cancer Lett; 2020 Jan; 469():355-366. PubMed ID: 31678168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biphasic co-detection of melanoma aneuploid tumor cells and tumor endothelial cells in guidance of specifying the field cancerized surgical excision margin and administering immunotherapy.
    Fu Z; Zhang L; Chen R; Zhan J; Zhong J; Zheng W; Zou J; Wang P; Deng X; Lin AY; Wang DD; Lin PP; He R
    Cancer Lett; 2024 Aug; 598():217099. PubMed ID: 38971491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas.
    Li M; Gao F; Ren X; Dong G; Chen H; Lin AY; Wang DD; Liu M; Lin PP; Shen S; Jiang H; Yang C; Zhang X; Zhao X; Zhu Q; Li M; Cui Y; Lin S
    Cancer Sci; 2022 Oct; 113(10):3535-3546. PubMed ID: 35940591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
    Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
    Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aneuploid subtypes of circulating tumor cells and circulating tumor-derived endothelial cells predict the overall survival of advanced lung cancer.
    Zhang J; Hong Y; Wang L; Hu W; Tian G; Wu D; Wang Y; Dai L; Zhang Z; Yang Y; Fang J
    Front Oncol; 2023; 13():829054. PubMed ID: 37213309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal detection of subcategorized CD44v6
    Wang Y; Zhang L; Tan J; Zhang Z; Liu Y; Hu X; Lu B; Gao Y; Tong L; Liu Z; Zhang H; Lin PP; Li B; Gires O; Zhang T
    Cancer Lett; 2023 Sep; 571():216337. PubMed ID: 37553013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of aneuploid circulating tumor cells and CD31
    Zhang T; Zhang L; Gao Y; Wang Y; Liu Y; Zhang H; Wang Q; Hu F; Li J; Tan J; Wang DD; Gires O; Lin PP; Li B
    Mol Oncol; 2021 Nov; 15(11):2891-2909. PubMed ID: 34455700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aneuploid Circulating Tumor-Derived Endothelial Cell (CTEC): A Novel Versatile Player in Tumor Neovascularization and Cancer Metastasis.
    Lin PP
    Cells; 2020 Jun; 9(6):. PubMed ID: 32599893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
    Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P
    Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.
    Kloten V; Lampignano R; Krahn T; Schlange T
    Cells; 2019 Aug; 8(8):. PubMed ID: 31374957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
    Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P
    Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tracking circulating PD-L1-positive cells to monitor the outcome of patients with gastric cancer receiving anti-HER2 plus anti-PD-1 therapy.
    Chong X; Li Y; Lu J; Feng X; Li Y; Zhang X
    Hum Cell; 2024 Jan; 37(1):258-270. PubMed ID: 37889437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
    Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q
    PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis.
    Zhu HH; Liu YT; Feng Y; Zhang LN; Zhang TM; Dong GL; Xing PY; Wang HY; Shi YK; Hu XS
    Thorac Cancer; 2021 Oct; 12(20):2749-2757. PubMed ID: 34423906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
    Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
    Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
    [No Abstract]   [Full Text] [Related]  

  • 16. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
    Koh Y; Yagi S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Higuchi M; Kanbara H; Nakanishi M; Ueda H; Yamamoto N
    Clin Lung Cancer; 2019 Jul; 20(4):270-277.e1. PubMed ID: 31005568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined detection of aneuploid circulating tumor-derived endothelial cells and circulating tumor cells may improve diagnosis of early stage non-small-cell lung cancer.
    Lei Y; Sun N; Zhang G; Liu C; Lu Z; Huang J; Zhang C; Zang R; Che Y; Mao S; Fang L; Wang X; Zheng S; He J
    Clin Transl Med; 2020 Jul; 10(3):e128. PubMed ID: 32659050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
    Sato M; Watanabe S; Tanaka H; Nozaki K; Arita M; Takahashi M; Shoji S; Ichikawa K; Kondo R; Aoki N; Hayashi M; Ohshima Y; Koya T; Ohashi R; Ajioka Y; Kikuchi T
    PLoS One; 2019; 14(4):e0215292. PubMed ID: 30978241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer.
    Zhou Q; Liu X; Li J; Tong B; Xu Y; Chen M; Liu X; Gao X; Shi Y; Zhao J; Zhong W; Wang M
    Thorac Cancer; 2023 Feb; 14(5):470-478. PubMed ID: 36630992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer.
    Sinoquet L; Jacot W; Gauthier L; Pouderoux S; Viala M; Cayrefourcq L; Quantin X; Alix-Panabières C
    Clin Chem; 2021 Nov; 67(11):1503-1512. PubMed ID: 34355741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.